Loading...
•
Jun 30, 2021
Caribou Biosciences Q2 2021 Earnings Report
Reported business highlights and financial results for the second quarter of 2021.
Key Takeaways
Caribou Biosciences reported a net loss of $14.3 million for the second quarter of 2021. The company completed an upsized IPO raising $349.6 million in gross proceeds and dosed the first patient in Phase 1 clinical trial of CB-010.
Dosed the first patient in Phase 1 clinical trial of CB-010.
Completed upsized IPO raising $349.6 million in gross proceeds.
Expanded Caribou’s board of directors with appointment of Nancy Whiting, Pharm.D.
Published data demonstrating the significantly improved specificity of Caribou’s proprietary CRISPR hybrid RNA-DNA (chRDNA) guide technology compared to all-RNA guides.
Revenue by Segment
Forward Guidance
Caribou expects initial data from the ongoing ANTLER Phase 1 trial in patients with relapsed or refractory B-NHL in 2022. Caribou expects to file an Investigational New Drug (IND) application for its CB-011 program in 2022. Caribou expects to file an IND application for its CB-012 program in 2023. Caribou expects to announce target selection for its CB-020 program in 2022.
Positive Outlook
- Initial data from the ongoing ANTLER Phase 1 trial in patients with relapsed or refractory B-NHL is expected in 2022.
- An Investigational New Drug (IND) application for its CB-011 program is expected to be filed in 2022.
- An IND application for its CB-012 program is expected to be filed in 2023.
- Target selection for its CB-020 program is expected to be announced in 2022.
- CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells engineered using Cas9 chRDNA technology.
Challenges Ahead
- Risks inherent in drug development
- Risks associated with the initiation, cost, timing, progress and results of current and future research and development programs
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...